# A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer

> **NCT05055232** · PHASE1 · COMPLETED · sponsor: **Xuanzhu Biopharmaceutical Co., Ltd.** · enrollment: 114 (actual)

## Conditions studied

- ROS1 Rearrangement Non-small Cell Lung Cancer
- ALK Rearrangement Non-small Cell Lung Cancer

## Interventions

- **DRUG:** XZP-3621

## Key facts

- **NCT ID:** NCT05055232
- **Lead sponsor:** Xuanzhu Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-12
- **Primary completion:** 2023-08-15
- **Final completion:** 2023-08-15
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05055232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05055232, "A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT05055232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*